Interrogating host immunity to predict treatment response in inflammatory bowel disease

IBD treatment is undergoing a transformation with an expanding repertoire of drugs targeting different aspects of the immune response. Three novel classes of drugs have emerged in the past decade that target leukocyte trafficking to the gut (vedolizumab), neutralize key cytokines with antibodies (us...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Gastroenterology & hepatology 2020-01, Vol.17 (1), p.9-20
Hauptverfasser:	Digby-Bell, Jonathan L., Atreya, Raja, Monteleone, Giovanni, Powell, Nick
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/249/2510/257 631/250/347 692/700/565 Biomedicine Care and treatment Cell Movement Clinical trials Corticosteroids Cytokines Cytokines - immunology Development and progression Drug delivery Drug development Drugs Endoscopy Endoscopy, Gastrointestinal Evaluation Gastroenterology Gastrointestinal Agents - therapeutic use Gene Expression Profiling Hepatology Humans Immune response Immunity (Disease) Immunohistochemistry Immunosuppressive agents Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - immunology Inflammatory Bowel Diseases - pathology Interleukin 23 Interleukin 6 Intestinal microflora Intestine Intravital Microscopy Janus Kinases - immunology Lymphocytes - immunology Lymphocytes - pathology Medicine Medicine & Public Health Microbiomes Microscopy, Confocal Monoclonal antibodies Mucosal immunity Observations Pathogenesis Patients Precision Medicine Prognosis Review Article Signal Transduction Treatment Outcome Tumor Necrosis Factor Inhibitors - therapeutic use Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!